Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

insertion sequence 110

- PMLiVE

Eli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m

The companies will use Genetic Leap's AI platform to generate oligonucleotide drugs against targets selected by Lilly

- PMLiVE

Vertex and Orum partner on gene editing conditioning drugs in deal worth $945m

The agreement gives Vertex the rights to use Orum’s targeted protein degradation technology

- PMLiVE

Scientists discover new form of gene editing to recombine and rearrange DNA

The bridge RNA system allows researchers to edit, delete and convert DNA recombinases without using CRISPR

regeneron headquarters

Regeneron and Mammoth announce gene editing partnership worth $370m per target

The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types

- PMLiVE

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Licenses two gene silencing programmes with up to $670m in the offing for the specialist

- PMLiVE

mRNA – message received

Assessing the growing pharma interest in modified messenger RNA

- PMLiVE

Janssen partners with Isis on stomach conditions

Will develop treatments that target RNA in people with autoimmune disorders

Silence Therapeutics appoints Michael Khan as chief medical adviser

Will advise on translational research for its siRNA-based therapeutics

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links